Your fact-checks will appear here
The development and review of drugs for treating Alzheimer's disease, including 182 clinical trials and 138 drugs in 2025
Clinical and preclinical literature describes repeated low-dose methylene blue (MB) as a candidate neuroprotective and memory‑enhancing agent via mitochondrial and anti‑oxidant actions, with human ima...
Two chemically related agents — classical (methylthioninium chloride, MTC) and a stabilized reduced derivative called hydromethylthionine (HMT; marketed as hydromethylthionine mesylate, HMTM or TRx023...
has a modest but consistent randomized clinical-trial footprint showing small improvements on some memory and attention tests across multiple placebo‑controlled trials and meta‑analyses . The current ...
Honey shows biological properties—antioxidant, anti-inflammatory, and polyphenol-driven activities—that lab studies and animal models suggest could be neuroprotective and might modestly affect pathway...
Approved, peer‑tested dementia treatments that have shown measurable slowing of cognitive decline in human trials remain the best-evidenced options today, while the interventions Elon Musk has promote...
Clinical research on huperzine‑A () includes dozens of small randomized trials—many conducted in —and a multicenter U.S. phase II trial; pooled analyses report short‑term cognitive benefits in (AD) bu...
appears to be the same pharmacologic agent as donepezil — a cholinesterase inhibitor used in that increases acetylcholine by inhibiting acetylcholinesterase . Its clinical risk comes less from foods a...